Novo Nordisk shares rise 2.7% after Lilly lifts its 2026 sales outlook to $91-92B
Novo reports nine-month results on Nov. 4, after a US judge declined its request to pause Lilly's weight-loss drug ads while the marketing dispute continues.
Recap by typeshit. Full story at ad-hoc-news.de.